Metagenomi, Inc. (MGX) — 10-Q Filings

10-Q Filings (5)

• Metagenomi's Revenue Plummets 59% as Losses Widen — Aug 12, 2025 Risk: high
  Metagenomi, Inc. (MGX) reported a significant decline in collaboration revenue for the six months ended June 30, 2025, falling to $12.64 million from $31.17 mil
• Metagenomi Files Q1 2025 10-Q, Details R&D and Agreements — May 13, 2025 Risk: medium
  Metagenomi, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses and general and administrative expe
• Metagenomi Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Metagenomi, Inc. filed its 10-Q for the period ending September 30, 2024. The company, focused on biological products, reported on its financial position and bu
• Metagenomi Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Metagenomi, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations.
• Metagenomi, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Metagenomi, Inc. (MGX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Metagenomi, Inc. filed a 10-Q report for the period ending March 31, 2024.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX